Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | PDE2A | O00408 | 11/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | YTHDF3 | Q7Z739 | 1/20 | 0.38 |
| ▸ | YTHDF1 | Q9BYJ9 | 1/20 | 0.38 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15660792 | 0.77 | JAK2 (0.44) | HIF1APDE2ATMIGD3ADORA1 | |
| SCHEMBL23716809 | 0.73 | DDB1 (0.47) | SMN1; SMN2PDE2AHTTTMIGD3ADORA1 | |
| SCHEMBL1535571 | 0.69 | PDE2A (0.53) | PDE2A | |
| SCHEMBL16867827 | 0.68 | PDE2A (0.52) | PDE2A | |
| SCHEMBL10852395 | 0.67 | SMN1; SMN2 (0.61) | SMN1; SMN2HIF1AHTT | |
| SCHEMBL10846547 | 0.67 | PKM (0.66) | SMN1; SMN2HIF1AHTT | |
| SCHEMBL2484820 | 0.66 | PDE2A (0.41) | PDE2A | |
| SCHEMBL10490276 | 0.64 | POLB (0.66) | SMN1; SMN2HIF1APDE2A | |
| Hydrochloric Acid SCHEMBL11372552 | 0.61 | HTR2B (0.45) | — | |
| SCHEMBL10854371 | 0.61 | PDE10A (0.34) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473790-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7148226-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, RNASEH1, NSUN3 | SMN1; SMN2 3095/4885HIF1A 805/4885PDE2A 1951/4885 |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, RNASEH1, NSUN3 | SMN1; SMN2 3095/4885HIF1A 805/4885PDE2A 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.